GlassScriptPhysician profile
Milagros A Martinez
NPI 1518131960
$1,909.66
in general payments reported to CMS, 2019-2025
25 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2021: $62.67 · 2022: $155 · 2023: $485 · 2024: $531 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $96.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.44 |
| Education | $96.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $304.53 | 2022-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $199.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.70 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $138.56 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $127.39 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $125.28 | 2021-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.72 | 2023-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $90.51 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $88.17 | 2019 | |
| Glaxosmithkline, LLC. | $82.13 | 2023-2025 | Benlysta, Jesduvroq |
| Cormedix INC. | $79.97 | 2024-2025 | Defencath, Defencath |
| Opko Pharmaceuticals, LLC | $79.82 | 2021-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $44.16 | 2023 | Soliris |
| Ani Pharmaceuticals, INC. | $38.95 | 2023-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $35.14 | 2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.27 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $29.03 | 2024 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $24.57 | 2025 | |
| Melinta Therapeutics, LLC | $22.42 | 2019 | |
| Scpharmaceuticals INC. | $21.94 | 2025 | |
| Amgen INC. | $21.69 | 2024 | Tavneos |
| Vifor Pharma, INC. | $18.37 | 2023 | Veltassa |
| Daiichi Sankyo INC. | $17.32 | 2023 | Injectafer |
| Ardelyx, INC. | $16.44 | 2024 | Ibsrela |
| Shield Therapeutics INC | $13.90 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milagros Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.